La fatica viene segnalata come il sintomo più comune nei pazienti con sclerosi multipla (SM). I parametri fisiologici e funzionali simili alla fatica nei pazienti con SM attualmente non sono ben definiti. Un nuovo sistema di misurazione wireless, denominato Fatigue Monitoring System (FAMOS), è stato sviluppato per studiare la fatica nella SM. Si può misurare costantemente l'elettrocardiogramma, corpo-temperatura corporea-cutanea, elettromiogramma e i movimenti dei piedi. L'obiettivo di questo studio è quello di verificare la capacità di distinguere pazienti con SM affaticati rispetto a soggetti sani, con l'uso di FAMOS. Questo documento presenta il sistema di misurazione includendodi hardware e algoritmi dedicati all'elaborazione del segnale.Ventisei i partecipanti, tra cui 17 pazienti con SM con fatica e 9 di sesso e di pari età sani sono stati inclusi nello studio per il monitoraggio continuo di 24 h. I risultati preliminari mostrano differenze significative tra pazienti affaticati con SM e sani. In conclusione, il FAMOS consente la continua acquisizione di dati e la stima di più parametri fisiologici e funzionali. Esso fornisce un approccio nuovo, flessibile e obiettivo di studiare la fatica nella SM, in grado di distinguere tra pazienti affaticati con SM e sani. L'utilizzabilità e l'affidabilità del FAMOS dovrebbe tuttavia essere ulteriormente migliorata e validata attraverso grandi studi clinici.
Fatigue is reported as the most common symptom by patients with multiple sclerosis (MS). The physiological and functional parameters related to fatigue in MS patients are currently not well established. A new wearable wireless body measurement system, named Fatigue Monitoring System (FAMOS), was developed to study fatigue in MS. It can continuously measure electrocardiogram, body-skin temperature, electromyogram and motions of feet. The goal of this study is to test the ability of distinguishing fatigued MS patients from healthy subjects by the use of FAMOS. This paper presents the realization of the measurement system including the design of both hardware and dedicated signal processing algorithms. Twenty-six participants including 17 MS patients with fatigue and 9 sex- and age-matched healthy controls were included in the study for continuous 24 h monitoring. The preliminary results show significant differences between fatigued MS patients and healthy controls. In conclusion, the FAMOS enables continuous data acquisition and estimation of multiple physiological and functional parameters. It provides a new, flexible and objective approach to study fatigue in MS, which can distinguish between fatigued MS patients and healthy controls. The usability and reliability of the FAMOS should however be further improved and validated through larger clinical trials.
Fatigue is reported as the most common symptom by patients with multiple sclerosis (MS). The physiological and functional parameters related to fatigue in MS patients are currently not well established. A new wearable wireless body measurement system, named Fatigue Monitoring System (FAMOS), was developed to study fatigue in MS. It can continuously measure electrocardiogram, body-skin temperature, electromyogram and motions of feet. The goal of this study is to test the ability of distinguishing fatigued MS patients from healthy subjects by the use of FAMOS. This paper presents the realization of the measurement system including the design of both hardware and dedicated signal processing algorithms. Twenty-six participants including 17 MS patients with fatigue and 9 sex- and age-matched healthy controls were included in the study for continuous 24 h monitoring. The preliminary results show significant differences between fatigued MS patients and healthy controls. In conclusion, the FAMOS enables continuous data acquisition and estimation of multiple physiological and functional parameters. It provides a new, flexible and objective approach to study fatigue in MS, which can distinguish between fatigued MS patients and healthy controls. The usability and reliability of the FAMOS should however be further improved and validated through larger clinical trials.
Commenti
Posta un commento